Dr. Tyrone C. Malloy: Hormone Replacement Therapy

 

Women’s Health-

 

Hormone Replacement

 

Therapy                                 A Multicenter, Double-Blind, randomized, Placebo-Controlled Study to determine the Lowest Effective Dose of Oral X for the Relief of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women Over a Treatment Period of 12 Weeks

 

Principal Investigator

 

Sponsor: Bayer HealthCare Pharmaceuticals 

 

 

 

A Phase 3A, double-blind, placebo-controlled, Randomized clinical trial assessing safety and efficacy of XXXXX for Hot flushes and Menopausal Symptoms in Postmenopausal Women.

 

Principal Investigator

 

Sponsor: BIONOVO, Inc. 

 

 

 

A Phase 3, 24 Week, Multicenter, Double-Blind, Randomized Placebo controlled Efficacy and Safety Study of XX capsules in the Treatment of Vasomotor Symptoms Associated with Menopause

 

Principal Investigator

 

Sponsor: Noven Therapeutics, LLC 

 

 

 

                                                A Phase 3, Twenty Four Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of XXXX Capsules in the Treatment of Vasomotor Symptoms Associated with Menopause

 

                                                Principal Investigator

 

                                                Sponsor: Noven Therapeutics  

 

 

 

A Phase 3, Twelve-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of XXXX Capsules in the Treatment of Vasomotor Symptoms Associated with Menopause

 

Principal Investigator

 

                                                Sponsor: Noven Therapeutics

 

 

 

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety and Efficacy of XXXX Tablets in the Treatment of Vasomotor Symptoms in Postmenopausal Women

 

Principal Investigator

 

Sponsor: Depomed, Inc.

 

 

 

A Phase 2b Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Evaluating The Efficacy And Safety of XX-XXXXX For The Treatment of Moderate To Severe Vasomotor Symptoms Associated With Menopause

 

                                                Principal Investigator

 

Sponsor: Pfizer-Sandwich Laboratories 

 

Joomla SEF URLs by Artio